1032. HCV Cascade of Care in A Single Veteranís Affairs Medical Center
Session: Poster Abstract Session: Hepatitis Viruses
Friday, October 9, 2015
Room: Poster Hall
Background: In the era of highly effective HCV therapy, barriers to patient movement through the cascade of ‎care are of increased importance.   Our objective was to describe the HCV cascade of care for HCV viremic patients in a large Veteran’s Affair Medical Center (VAMC).

Methods: We used a population-level electronic health record to extract information on HCV viremic patients in the Greater Los Angeles VAMC from May 2013 to May 2015.  Advanced fibrosis was defined as a FIB4>3.25.  The cascade of care was defined as 1) HCV viremic veterans, 2) number referred for specialty care, 3) number evaluated in clinic, 4) number treated, and 5) number with SVR. Referrals were defined as a referral to an ID/GI clinic and evaluation for treatment was met if the patient attended an ID/GI clinic appointment.

Results: There were 4538 veterans with HCV viremia, of these 3230 (71%) were referred to hepatitis C care, 1624 (36%) were evaluated for treatment, 949 (21%) received therapy, and 449/4538 (10%) achieved a sustained virologic response (SVR12).  Advanced fibrosis was present in 801/4538 (18%) of HCV viremic patients; of whom 632 (79%) were referred for care, 309 (39%) were evaluated for treatment, 201(25%) received therapy, and 68 (8.0%) had an SVR12.  

Conclusion: In a single-center VAMC, the majority of HCV viremic veterans are referred to HCV care but only 36% and 21% are evaluated for treatment and received treatment, respectively. Once evaluated, >50% patients received treatment. Rates were similar in those with advanced fibrosis.   Potential barriers in linkage to care may include distance from clinic and gaps in patient education.    Identifying barriers to care and designing targeted interventions will be important in ensuring treatment for HCV infected veterans, particularly those with advanced fibrosis.

Debika Bhattacharya, MD, MSc1,2, Hemen Saifu, MPH1, Tuyen Hoang, PhD1, William a. Schwartzman, M.D.3, Alan Sheinbaum, MD1, Pamela Belperio, PharmD4 and Matthew Bidwell Goetz, MD1,5, (1)VA Greater Los Angeles Healthcare System, Los Angeles, CA, (2)University of California, Los Angeles, Los Angeles, CA, (3)Infectious Diseases, VA Greater Los Angeles Healthcare System, Los Angeles, CA, (4)Pharmacy, VA Greater Los Angeles Heathcare system, Los Angeles, CA, (5)David Geffen School of Medicine at UCLA, Los Angeles, CA

Disclosures:

D. Bhattacharya, Bristol Myers Squibb: Collaborator , Research support
Abbvie: Collaborator , Research support

H. Saifu, None

T. Hoang, None

W. A. Schwartzman, None

A. Sheinbaum, Gilead: Collaborator , Research support

P. Belperio, None

M. Bidwell Goetz, None

See more of: Hepatitis Viruses
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.